Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.32 |
| ▸ | CA12 | O43570 | 1/20 | 0.31 |
| ▸ | F2 | P00734 | 1/20 | 0.30 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.30 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.30 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31565133 | 1.00 | CA14 (0.32) | CA14CA12F2PRSS1PRSS2 | |
| SCHEMBL27028872 | 0.85 | MAPK1 (0.32) | CA14CA12CA1CA2 | |
| SCHEMBL20399144 | 0.85 | MAPT (0.32) | CA14CA1CA2 | |
| SCHEMBL29097128 | 0.85 | MAPK1 (0.32) | CA14CA12CA1CA2 | |
| SCHEMBL20399145 | 0.85 | MAPT (0.32) | CA14CA1CA2 | |
| SCHEMBL27301372 | 0.85 | MAPK1 (0.32) | CA14CA12CA1CA2 | |
| SCHEMBL21261493 | 0.84 | CA1 (0.38) | CA14CA12F2PRSS1PRSS2 | |
| SCHEMBL15382587 | 0.84 | CA1 (0.38) | CA14CA12F2PRSS1PRSS2 | |
| SCHEMBL2332745 | 0.84 | CA1 (0.38) | CA14CA12F2PRSS1PRSS2 | |
| SCHEMBL1576198 | 0.81 | MME (0.39) | CA14CA12MEN1KMT2ACA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025093755-A1 | NOVEL PARC INHIBITORS | FORX THERAPEUTICS AG (CH) | 2025-05-08 | — | — | WO | disclosed |